Recent years, more and more men had been diagnosed with prostate cancer in Taiwan. In early stage of prostate cancer, the radical prostatectomy is the best method of surgical therapy for these men. In a population investigation after radical prostatectomy only 6.7% of organ-confined prostate cancer patients did not complain about erectile dysfunction. Despite attempts to spare the cavernous nerves, only 13-56% of men do not lose their erectile dysfunction after surgery for prostate carcinoma. However, platelets play a fundamental role not only in coagulation but also in regulation of body metabolism and promotion of the wound healing and tissue regeneration. When platelets are activated, they will release many kinds of growth differentiation factor, and a few have been found to facilitate nerve repair and regeneration. Although many researches of the related platelets were undergoing, the related protocol for platelet-rich fibrin gel releasing more growth factor was not evaluated. And the exact mechanism about the relationship between platelet-rich fibrin and regeneration of nerve is not clear and need further studies to get more evidence and evaluate the possibility on clinical application of retaining erectile function. Within this study, we aimed at the improvement of a platelet-rich fibrin gel in order to release more growth factor and subsequently, investigated the relationship between platelet-rich fibrin glue and regeneration of nerve for in vitro studies and in animal model. In the first year, we will try to compare the effects of platelet-rich fibrin glue preparation with variant activating factor on releasing the growth factor. In the second year, we will assess the effects and the mechanism between fibrin glue and human neuroblastoma cells in vitro test. In the third year, we will establish bilateral cavernous nerve injury rat models which mimic patients who experienced radical prostatectomy to determine the effects of platelet-rich fibrin glue on the recovery of erectile function and its mechanism in rat model.
|Effective start/end date||8/1/11 → 7/31/12|
- erectile dysfunction
- growth factor
- platelet-rich plasma
- radical prostatectomy